<div id="readability-page-1"><p>Analyst Craig Hettenbach of Morgan Stanley maintained a Hold rating on Hims &amp; Hers Health, retaining the price target of $21.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Craig Hettenbach has given his Hold rating due to a combination of factors related to Hims &amp; Hers Health’s growth strategy and profitability profile. Management is aggressively pursuing revenue expansion and even raised its longer-term sales outlook, yet this comes alongside reduced EBITDA guidance and a notable decline in gross margins, signaling profitability pressure and the need for investor patience.</p> <p>At the same time, the company delivered its first EBITDA miss, with Q1 results falling short of Street expectations and near-term EBITDA guidance sitting below consensus despite stronger top-line targets. While international performance and the renewed Novo partnership are encouraging, Hettenbach believes the stock’s upside is constrained until there is clearer evidence of sustainable margin improvement and positive EBITDA revisions, supporting a Hold rating and an unchanged $21 price target. </p> <p>In another report released today, Citi also assigned a Hold rating to the stock with a $28.00 price target.</p></div>

HIMS

HIMZ

HIMY

<p>Analyst Craig Hettenbach of Morgan Stanley has maintained a Hold rating on Hims & Hers Health, reiterating a price target of $21.00. The decision is based on the company's aggressive revenue expansion efforts, which are accompanied by reduced EBITDA guidance and declining gross margins, indicating profitability pressures. Despite a strong top-line performance, the company missed its first EBITDA expectations. Citi also assigned a Hold rating with a $28.00 price target, reflecting concerns over sustainable margin improvement and positive EBITDA revisions.</p>

Tip Ranks

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

Health Care Select Sector SPDR

Defiance Leveraged Long +Income HIMS ETF

VG Health

iShares Global Healthcare

iShares US Healthcare Providers

SPDR S&P Health

Morgan Stanley

Citigroup

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated